{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Patients+With+Prostate+Cancer&page=2",
    "query": {
      "condition": "Patients With Prostate Cancer",
      "page": 2
    },
    "page_size": 10
  },
  "pagination": {
    "page": 2,
    "page_size": 10,
    "total_count": 10,
    "total_pages": 1,
    "next_page_url": null,
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Patients+With+Prostate+Cancer&page=1&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-07-23T14:19:26.382Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT04742959",
      "title": "Study of TT-00420 (Tinengotinib) Tablet as Monotherapy and Combination Therapy in Patients With Advanced Solid Tumors",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Advanced Solid Tumor",
        "Cholangiocarcinoma",
        "HER2-negative Breast Cancer",
        "Triple Negative Breast Cancer",
        "Bladder Cancer",
        "Small-cell Lung Cancer",
        "Prostate Cancer",
        "Thyroid Cancer",
        "Sarcoma",
        "Gastric Cancer",
        "Gallbladder Cancer"
      ],
      "interventions": [
        {
          "name": "TT-00420",
          "type": "DRUG"
        },
        {
          "name": "Nab-Paclitaxel",
          "type": "COMBINATION_PRODUCT"
        }
      ],
      "intervention_types": [
        "DRUG",
        "COMBINATION_PRODUCT"
      ],
      "sponsor": "TransThera Sciences (Nanjing), Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 203,
      "start_date": "2021-03-14",
      "completion_date": "2024-02-20",
      "has_results": false,
      "last_update_posted_date": "2024-04-26",
      "last_synced_at": "2026-07-23T14:19:26.382Z",
      "location_count": 6,
      "location_summary": "Duarte, California • Chicago, Illinois • New Brunswick, New Jersey + 3 more",
      "locations": [
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "New Brunswick",
          "state": "New Jersey"
        },
        {
          "city": "Canton",
          "state": "Ohio"
        },
        {
          "city": "Dallas",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04742959"
    },
    {
      "nct_id": "NCT04424641",
      "title": "A Study on the Safety of GEN1044 (DuoBody®-CD3x5T4) in Patients With Malignant Solid Tumors",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Locally Advanced or Metastatic Solid Tumor(s)",
        "Prostate Cancer",
        "Esophageal Cancer",
        "Triple Negative Breast Cancer (TNBC)",
        "Squamous Cell Carcinoma of Head and Neck (SCCHN)",
        "Non-small Cell Lung Cancer (NSCLC)",
        "Bladder Cancer",
        "Uterine Cancer"
      ],
      "interventions": [
        {
          "name": "GEN1044 is an immunoglobulin G1 (IgG1) bispecific antibody targeting CD3 and 5T4.",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Genmab",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 48,
      "start_date": "2020-07-15",
      "completion_date": "2021-10-29",
      "has_results": true,
      "last_update_posted_date": "2023-07-25",
      "last_synced_at": "2026-07-23T14:19:26.382Z",
      "location_count": 2,
      "location_summary": "Nashville, Tennessee • Houston, Texas",
      "locations": [
        {
          "city": "Nashville",
          "state": "Tennessee"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04424641"
    },
    {
      "nct_id": "NCT01528774",
      "title": "Culture and Characterization of Circulating Tumor Cells (CTC) in Melanoma and Other Cancers",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Melanoma"
      ],
      "interventions": [
        {
          "name": "Blood Draw",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "Wolfram Samlowski",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 150,
      "start_date": "2016-06",
      "completion_date": "2016-06",
      "has_results": false,
      "last_update_posted_date": "2017-07-26",
      "last_synced_at": "2026-07-23T14:19:26.382Z",
      "location_count": 1,
      "location_summary": "Las Vegas, Nevada",
      "locations": [
        {
          "city": "Las Vegas",
          "state": "Nevada"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01528774"
    },
    {
      "nct_id": "NCT01735396",
      "title": "Abiraterone Acetate Trial in African American Prostate Cancer Patients",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Prostate Cancer"
      ],
      "interventions": [
        {
          "name": "Abiraterone Acetate",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Icahn School of Medicine at Mount Sinai",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "MALE",
        "summary": "18 Years and older · Male only"
      },
      "enrollment_count": 11,
      "start_date": "2012-12",
      "completion_date": "2016-03",
      "has_results": true,
      "last_update_posted_date": "2017-05-12",
      "last_synced_at": "2026-07-23T14:19:26.382Z",
      "location_count": 2,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01735396"
    },
    {
      "nct_id": "NCT00748046",
      "title": "Alpharadin™ (Radium-223 Chloride) Safety and Dosimetry With HRPC That Has Metastasized to the Skeleton",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Prostate Cancer",
        "Metastases",
        "Pharmacokinetics"
      ],
      "interventions": [
        {
          "name": "Radium-223 chloride (BAY88-8223)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Bayer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "MALE",
        "summary": "18 Years and older · Male only"
      },
      "enrollment_count": 10,
      "start_date": "2008-08",
      "completion_date": "2009-10",
      "has_results": false,
      "last_update_posted_date": "2014-06-25",
      "last_synced_at": "2026-07-23T14:19:26.382Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00748046"
    },
    {
      "nct_id": "NCT02326805",
      "title": "PROSTVAC (PSA-TRICOM) in Preventing Disease Progression in Patients With Localized Prostate Cancer Undergoing Active Surveillance",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Stage I Prostate Adenocarcinoma AJCC v7",
        "Stage II Prostate Adenocarcinoma AJCC v7"
      ],
      "interventions": [
        {
          "name": "Laboratory Biomarker Analysis",
          "type": "OTHER"
        },
        {
          "name": "Placebo Administration",
          "type": "OTHER"
        },
        {
          "name": "Rilimogene Galvacirepvec",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "OTHER",
        "BIOLOGICAL"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "MALE",
        "summary": "Male only"
      },
      "enrollment_count": 154,
      "start_date": "2015-06-03",
      "completion_date": "2022-07-20",
      "has_results": true,
      "last_update_posted_date": "2023-07-19",
      "last_synced_at": "2026-07-23T14:19:26.382Z",
      "location_count": 7,
      "location_summary": "Los Angeles, California • Newport Beach, California • Orange, California + 3 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Newport Beach",
          "state": "California"
        },
        {
          "city": "Orange",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02326805"
    },
    {
      "nct_id": "NCT01267266",
      "title": "Saracatinib in Treating Patients With Prostate Cancer",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Hormone-resistant Prostate Cancer",
        "Recurrent Prostate Cancer",
        "Stage IV Prostate Cancer"
      ],
      "interventions": [
        {
          "name": "saracatinib",
          "type": "DRUG"
        },
        {
          "name": "hydrocortisone/placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "MALE",
        "summary": "Male only"
      },
      "enrollment_count": 31,
      "start_date": "2010-12",
      "completion_date": "2013-11",
      "has_results": true,
      "last_update_posted_date": "2015-04-01",
      "last_synced_at": "2026-07-23T14:19:26.382Z",
      "location_count": 15,
      "location_summary": "Chicago, Illinois • Decatur, Illinois • Evanston, Illinois + 11 more",
      "locations": [
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Decatur",
          "state": "Illinois"
        },
        {
          "city": "Evanston",
          "state": "Illinois"
        },
        {
          "city": "Harvey",
          "state": "Illinois"
        },
        {
          "city": "Maywood",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01267266"
    },
    {
      "nct_id": "NCT00002874",
      "title": "Radiation Therapy With or Without Bicalutamide for Recurrent pT3N0 Prostate Cancer After Radical Prostatectomy",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Prostate Cancer"
      ],
      "interventions": [
        {
          "name": "bicalutamide",
          "type": "DRUG"
        },
        {
          "name": "radiation therapy",
          "type": "RADIATION"
        },
        {
          "name": "placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG",
        "RADIATION"
      ],
      "sponsor": "Radiation Therapy Oncology Group",
      "sponsor_class": "NETWORK",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "MALE",
        "summary": "Male only"
      },
      "enrollment_count": 840,
      "start_date": "1998-02",
      "completion_date": "2022-05-20",
      "has_results": true,
      "last_update_posted_date": "2022-06-15",
      "last_synced_at": "2026-07-23T14:19:26.382Z",
      "location_count": 221,
      "location_summary": "Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 168 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Huntsville",
          "state": "Alabama"
        },
        {
          "city": "Huntsville",
          "state": "Alabama"
        },
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Montgomery",
          "state": "Alabama"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00002874"
    },
    {
      "nct_id": "NCT00032006",
      "title": "Hormone Therapy Followed By Internal Radiation Therapy in Treating Patients With Locally Recurrent Prostate Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Prostate Cancer"
      ],
      "interventions": [
        {
          "name": "brachytherapy",
          "type": "RADIATION"
        },
        {
          "name": "radiation therapy",
          "type": "RADIATION"
        }
      ],
      "intervention_types": [
        "RADIATION"
      ],
      "sponsor": "Alliance for Clinical Trials in Oncology",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "MALE",
        "summary": "18 Years and older · Male only"
      },
      "enrollment_count": 48,
      "start_date": "2002-02",
      "completion_date": "2003-10",
      "has_results": false,
      "last_update_posted_date": "2016-07-13",
      "last_synced_at": "2026-07-23T14:19:26.382Z",
      "location_count": 8,
      "location_summary": "Scottsdale, Arizona • Jacksonville, Florida • Urbana, Illinois + 5 more",
      "locations": [
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Jacksonville",
          "state": "Florida"
        },
        {
          "city": "Urbana",
          "state": "Illinois"
        },
        {
          "city": "Des Moines",
          "state": "Iowa"
        },
        {
          "city": "Rochester",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00032006"
    },
    {
      "nct_id": "NCT00035997",
      "title": "Open-label Trial on the Effect of I.V. Zoledronic Acid 4 mg on Bone Density in Hormone Sensitive Prostate Cancer Patients With Bone Metastasis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Prostate Cancer"
      ],
      "interventions": [
        {
          "name": "Zometa",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Novartis Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "MALE",
        "summary": "18 Years and older · Male only"
      },
      "enrollment_count": 261,
      "start_date": "2002-04",
      "completion_date": "2004-01",
      "has_results": false,
      "last_update_posted_date": "2009-11-23",
      "last_synced_at": "2026-07-23T14:19:26.382Z",
      "location_count": 56,
      "location_summary": "Birmingham, Alabama • Anchorage, Alaska • Anaheim, California + 50 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Anchorage",
          "state": "Alaska"
        },
        {
          "city": "Anaheim",
          "state": "California"
        },
        {
          "city": "Fresno",
          "state": "California"
        },
        {
          "city": "La Mesa",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00035997"
    }
  ]
}